CD8A and neoplasm: In a 4T1 breast cancer mouse model, Immunomax® significantly improved survival; inhibited tumor growth and metastasis; increased the percentage of NK cells, CD4+T cells, and CD8+T cells in the mouse spleen; and significantly reduced the percentage of bone marrow-derived suppressor cells (MDSCs), making it a potential anti-cancer drug candidate [136].